Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

189.15 +1.94 (+1.04%)
Streaming Delayed Price Updated: 3:24 PM EDT, May 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
59 60 Next >
News headline image
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe ↗
Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns. 
Via Benzinga
News headline image
Large-Cap Stocks In Trouble - Sunday, Oct. 13 ↗
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
News headline image
The Latest Analyst Ratings For Biogen ↗
 
Via Benzinga
News headline image
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays. 
Via MarketBeat
Topics ETFs Earnings
News headline image
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
From Biogen Inc.
Via GlobeNewswire
News headline image
Looking Into Biogen's Recent Short Interest ↗
 
Via Benzinga
News headline image
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study ↗
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%. 
Via Benzinga
News headline image
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year ↗
Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... 
Via Benzinga
News headline image
Forecasting The Future: 20 Analyst Projections For Biogen ↗
 
Via Benzinga
News headline image
Key Takeaways From Biogen Analyst Ratings ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Biogen ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Biogen? ↗
 
Via Benzinga
News headline image
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030 ↗
It's hard to bet against this company right now. 
Via The Motley Fool
News headline image
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate ↗
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February... 
Via Benzinga
News headline image
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial ↗
UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48... 
Via Benzinga
News headline image
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Board Appoints Two New Independent Directors
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development 
From Biogen Inc.
Via GlobeNewswire
News headline image
Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know ↗
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately. 
Via Benzinga
News headline image
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' ↗
 
Via Benzinga
News headline image
Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges ↗
Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the benefits, but challenges with side effects, insurance, and diagnostics... 
Via Benzinga
News headline image
Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder ↗
Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor function in treatment-naïve infants with spinal muscular atrophy, compared... 
Via Benzinga
News headline image
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
From Biogen Inc.
Via GlobeNewswire
News headline image
These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now ↗
This competitive showdown just saw one of the players hit a couple of bumps. 
Via The Motley Fool
News headline image
Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker ↗
Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space. 
Via Benzinga
News headline image
Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential ↗
PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets ranging from $84 to $185. 
Via Benzinga
News headline image
Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety ↗
The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed. 
Via Benzinga
News headline image
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement ↗
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated... 
Via Benzinga
News headline image
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
News headline image
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys. ↗
These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.